Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1033

1.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481
2.

Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

BJU Int. 2015 Jul;116(1):30-6. doi: 10.1111/bju.13026. Epub 2015 Mar 23. Review.

3.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

4.

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.

Wuntakal R, Seshadri S, Montes A, Lane G.

Cochrane Database Syst Rev. 2016 Jun 29;(6):CD011322. doi: 10.1002/14651858.CD011322.pub2. Review.

PMID:
27356090
5.

Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.

Chen XQ, Huang Y, Li X, Zhang P, Huang R, Xia J, Chen N, Wei Q, Zhu YC, Yang YR, Zeng H.

Asian J Androl. 2010 Sep;12(5):718-27. doi: 10.1038/aja.2010.42. Epub 2010 Aug 9.

6.

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.

Ann Intern Med. 2000 Apr 4;132(7):566-77. Erratum in: Ann Intern Med. 2005 Nov 15;143(10):764-5.

PMID:
10744594
7.

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.

Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT.

Urology. 1995 Dec;46(6):849-55.

PMID:
7502428
8.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.

Eur Urol. 1996;29 Suppl 2:105-9.

PMID:
8717471
9.

Interventions for hirsutism (excluding laser and photoepilation therapy alone).

van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N.

Cochrane Database Syst Rev. 2015 Apr 28;(4):CD010334. doi: 10.1002/14651858.CD010334.pub2. Review.

12.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
13.

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):48-51. Review.

PMID:
23444510
14.

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N.

Cancer. 2002 Jul 15;95(2):361-76. Review.

15.
16.

Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.

Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.

Urology. 2009 Mar;73(3):635-40. doi: 10.1016/j.urology.2008.09.013. Epub 2008 Nov 26.

PMID:
19038426
17.

Fulvestrant for hormone-sensitive metastatic breast cancer.

Lee CI, Goodwin A, Wilcken N.

Cochrane Database Syst Rev. 2017 Jan 3;1:CD011093. doi: 10.1002/14651858.CD011093.pub2. Review.

PMID:
28043088
18.

Non-surgical versus surgical treatment for oesophageal cancer.

Best LM, Mughal M, Gurusamy KS.

Cochrane Database Syst Rev. 2016 Mar 29;3:CD011498. doi: 10.1002/14651858.CD011498.pub2. Review.

PMID:
27021481
19.

Antiandrogen monotherapy in the management of advanced prostate cancer.

Kaisary AV.

Eur Urol. 1997;31 Suppl 2:14-9; discussion 24-7.

PMID:
9074906
20.

[First line therapy in the treatment of metastatic prostate cancer].

Sakai H, Kanetake H.

Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9. Review. Japanese.

PMID:
12557704

Supplemental Content

Support Center